glp-1 gip news π¨ Big for people with type 1 diabetes who are using or are interested in using a GLP-1! 35 new recommendations have been published for use of GLP-1s and GLP-1/GIP in π¨ Big news for people
Description
The case is strong and getting stronger
Both its dual-agonist injectable poterepatide and its oral small molecule conveglipron are in Phase III, demonstrating significant late-stage momentum
How retatrutide works: the first triple agonist targeting GIP, GLP-1, and glucagon receptors
Promotes Lean Muscle & Fat Reduction*
